Electrome

Executive Summary

Electrome is a San Francisco-based biotech company founded in 2021 that is pioneering precision bioelectric therapeutics. By decoding and modulating the body's native electrical signaling, Electrome aims to develop non-invasive neuromodulation therapies for pain, infection, and cancer. The company integrates an AI-driven discovery engine with a scalable hardware platform to accelerate the development of 'electroceuticals.' This approach leverages the body's own electrical language to treat disease with high specificity and minimal side effects. While still in early stages, Electrome's platform has the potential to address large unmet medical needs across multiple therapeutic areas. The company has not yet disclosed funding or clinical milestones, but its innovative technology and experienced team position it for growth. Key near-term catalysts include securing Series A financing, initiating first-in-human studies, and forming strategic partnerships with pharmaceutical or medical device companies.

Upcoming Catalysts (preview)

• 2026Series A Funding Announcement70% success
• 2027FDA IND Submission for Lead Program50% success
• TBDStrategic Partnership with Pharma or Medtech40% success